加拿大和意大利艰难梭菌菌株对利福霉素的不同敏感性及利福平 Etest 预测利福霉素耐药性的准确性。
Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.
机构信息
Clinical Microbiology, Jewish General Hospital, 3755 Cote Ste. Catherine Rd., Montreal, QC H3T 1E2, Canada.
出版信息
J Clin Microbiol. 2011 Dec;49(12):4319-21. doi: 10.1128/JCM.05100-11. Epub 2011 Oct 12.
Abstract
We tested the activities of rifampin (RIF) and rifaximin (RFX) against 180 Clostridium difficile clinical isolates selected from Canadian and Italian culture collections. MICs were determined by CLSI agar dilution for both drugs and by Etest for RIF. Sixteen of 85 Italian isolates (18.8%) showed high-level resistance to both rifamycins (MICs, >16 μg/ml), compared to 2 of 95 (2.1%) Canadian isolates. Two new rpoB mutations were identified in rifamycin-resistant isolates. RIF susceptibility by Etest correlated completely with susceptibility to both rifamycins determined by agar dilution.
摘要
我们测试了利福平（RIF）和利福昔明（RFX）对 180 株来自加拿大和意大利菌种库的艰难梭菌临床分离株的活性。两种药物的 MIC 均通过 CLSI 琼脂稀释法测定，RIF 的 MIC 则通过 Etest 测定。与 95 株加拿大分离株中的 2 株（2.1%）相比，85 株意大利分离株中有 16 株（18.8%）对两种利福霉素均显示高水平耐药。在耐药株中鉴定出两种新的 rpoB 突变。Etest 法检测的 RIF 敏感性与琼脂稀释法检测的两种利福霉素的敏感性完全相关。
相似文献
1
Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.
J Clin Microbiol. 2011 Dec;49(12):4319-21. doi: 10.1128/JCM.05100-11. Epub 2011 Oct 12.
2
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
Antimicrob Agents Chemother. 2008 Aug;52(8):2813-7. doi: 10.1128/AAC.00342-08. Epub 2008 Jun 16.
3
Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.
J Med Microbiol. 2011 Aug;60(Pt 8):1206-1212. doi: 10.1099/jmm.0.028571-0. Epub 2011 Feb 3.
4
High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.
Clin Infect Dis. 2009 Feb 15;48(4):425-9. doi: 10.1086/596315.
5
In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.
Antimicrob Agents Chemother. 2012 Nov;56(11):6019-20. doi: 10.1128/AAC.00974-12. Epub 2012 Aug 20.
6
Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
Tuberculosis (Edinb). 2011 Sep;91(5):361-9. doi: 10.1016/j.tube.2011.05.002. Epub 2011 Jun 24.
7
In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.
Antimicrob Agents Chemother. 2011 Mar;55(3):992-6. doi: 10.1128/AAC.00688-10. Epub 2010 Dec 13.
8
Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5604-7. doi: 10.1128/AAC.01137-16. Print 2016 Sep.
9
High-resolution melting analysis of the single nucleotide polymorphism hot-spot region in the rpoB gene as an indicator of reduced susceptibility to rifaximin in Clostridium difficile.
J Med Microbiol. 2012 Jun;61(Pt 6):780-785. doi: 10.1099/jmm.0.041087-0. Epub 2012 Feb 23.
10
Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.
Antimicrob Agents Chemother. 2013 Jun;57(6):2690-3. doi: 10.1128/AAC.00548-13. Epub 2013 Apr 1.
引用本文的文献
1
Antibiotic Resistances of Clostridioides difficile.
Adv Exp Med Biol. 2024;1435:169-198. doi: 10.1007/978-3-031-42108-2_9.
2
The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.
Clin Microbiol Rev. 2023 Dec 20;36(4):e0003923. doi: 10.1128/cmr.00039-23. Epub 2023 Nov 16.
3
Antimicrobial resistance in Clostridioides difficile.
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2459-2478. doi: 10.1007/s10096-021-04311-5. Epub 2021 Aug 24.
4
Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158. doi: 10.1186/s13756-020-00815-5.
5
Conventional and alternative treatment approaches for infection.
Int J Health Sci (Qassim). 2017 Jan-Mar;11(1):1-10.
6
Management of a cluster of infections among patients with osteoarticular infections.
Antimicrob Resist Infect Control. 2017 Feb 15;6:22. doi: 10.1186/s13756-017-0181-4. eCollection 2017.
7
Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.
Eur J Clin Microbiol Infect Dis. 2017 Jan;36(1):163-175. doi: 10.1007/s10096-016-2790-x. Epub 2016 Sep 30.
8
Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.
Ther Adv Infect Dis. 2016 Feb;3(1):23-42. doi: 10.1177/2049936115622891.
9
Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance.
Genes (Basel). 2015 Dec 21;6(4):1347-60. doi: 10.3390/genes6041347.
10
Clostridium difficile infection among hospitalized HIV-infected individuals: epidemiology and risk factors: results from a case-control study (2002-2013).
BMC Infect Dis. 2015 Apr 22;15:194. doi: 10.1186/s12879-015-0932-x.
本文引用的文献
1
Treatment of clostridium difficile infection.
Med Lett Drugs Ther. 2011 Feb 21;53(1358):14-5.
2
Fidaxomicin versus vancomycin for Clostridium difficile infection.
N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.
3
Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom.
Clin Infect Dis. 2010 Jun 15;50(12):e77-81. doi: 10.1086/653012.
4
In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas.
J Clin Pathol. 2010 Apr;63(4):355-8. doi: 10.1136/jcp.2009.071688.
5
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.
Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d.
6
High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.
Clin Infect Dis. 2009 Feb 15;48(4):425-9. doi: 10.1086/596315.
7
Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.
Antimicrob Agents Chemother. 2009 Jan;53(1):223-8. doi: 10.1128/AAC.01442-07. Epub 2008 Oct 27.
8
Emergence of reduced susceptibility to metronidazole in Clostridium difficile.
J Antimicrob Chemother. 2008 Nov;62(5):1046-52. doi: 10.1093/jac/dkn313. Epub 2008 Aug 7.
9
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
Antimicrob Agents Chemother. 2008 Aug;52(8):2813-7. doi: 10.1128/AAC.00342-08. Epub 2008 Jun 16.
10
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
Ann Pharmacother. 2008 Jun;42(6):827-35. doi: 10.1345/aph.1K675. Epub 2008 Apr 22.
Zotero 插件